Status:
RECRUITING
Non-invasive Spinal Cord Stimulation for Recovery of Autonomic Function After Spinal Cord Injury
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
United States Department of Defense
Congressionally Directed Medical Research Programs
Conditions:
Spinal Cord Injury
Autonomic Dysfunction
Eligibility:
All Genders
19-60 years
Phase:
NA
Brief Summary
This study is a pilot clinical trial to explore the efficacy of transcutaneous spinal cord stimulation (TCSCS) (proof-of-concept) in mitigating crucial autonomic dysfunctions that impact the health-re...
Detailed Description
This is a pilot clinical trial to explore the efficacy of TCSCS (proof-of-concept) in mitigating crucial autonomic dysfunctions that impact the health-related quality of life of individuals with SCI. ...
Eligibility Criteria
Inclusion
- Resident of British Columbia, Canada with active provincial medical services plan.
- Male or female, 19-60 years of age.
- Chronic traumatic SCI (non-progressive, with complete motor paralysis) at or above the T6 spinal segment.
- \>1-year post injury, at least 6 months from any spinal surgery.
- American Spinal Injury Association Impairment Scale (AIS) A, B.
- Stable management of spinal cord related clinical issues (i.e., spasticity management).
- Experience bladder, or bowel, or sexual dysfunction.
- No painful musculoskeletal dysfunction, unhealed fracture, pressure sore, or active infection that may interfere with testing.
- For women of childbearing potential, not intending to become pregnant, currently pregnant, or lactating. The following conditions apply:
- A confirmed negative pregnancy test prior to the baseline visit. During the trial, all women of childbearing potential will undergo urine pregnancy tests at their monthly clinic visits as outlined in the schedule of events.
- Use adequate contraception, or complete abstinence from sexual activities, during the period of the trial and for at least 28 days after completion of treatment.
- If using combined hormonal contraception, a stable regimen during the period of the trial and for at least 28 days after completion of treatment.
- For sexually active males with female partners of childbearing potential, use adequate contraception, or complete abstinence from sexual activities, during the period of the trial and for at least 28 days after completion of treatment.
- Must provide informed consent.
- Willing and able to comply with all clinic visits and study-related procedures.
- Able to understand and complete study-related questionnaires (must be able to understand and speak English or have access to an appropriate interpreter as judged by the investigator).
Exclusion
- Ventilator dependent.
- Signs of lower motor neuron damage (i.e. concomitant conus medullaris/cauda equina injury).
- Severe anemia or hypovolemia as measured by hematocrit via blood test in the last six months.
- History of cardiovascular, respiratory, bladder, or renal disease unrelated to SCI or presence of hydronephrosis or presence of obstructive renal stones.
- History of seizures/epilepsy or recurring headaches.
- Clinically significant, unmanaged, depression (to be screened) or ongoing drug abuse.
- Intrathecal baclofen pump.
- Oral baclofen dose greater than 60mg.
- Individuals that have received intradetrusor or intrasphincter onabotulinumtoxinA injections within 6 months of baseline.
- Any implanted metal (other than dental implants) in the skull or presence of pacemakers, stimulators, or medication pumps in the trunk.
- Past electrode implantation surgery.
- Member of the investigational team or his/her immediate family.
- Presence of severe acute medical issue and use of any specific medication or treatment that, in the investigator's judgement, would adversely affect the participant's participation in the study.
- Known allergies or sensitivities to both blue dye and beetroot powder.
- Known or suspected gastrointestinal obstruction.
- Persons with active inflammatory bowel disease or a history of bowel perforation.
Key Trial Info
Start Date :
October 3 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05369520
Start Date
October 3 2023
End Date
October 1 2027
Last Update
December 8 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Blusson Spinal Cord Centre
Vancouver, British Columbia, Canada, V5Z 1M9
2
St Paul's Hospital
Vancouver, British Columbia, Canada, V6Z 1Y6